Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Micromet, a biopharmaceutical company developing antibodies for the treatment of cancer, inflammation and autoimmune diseases, has appointed Kapil Dhingra to its board of directors. As a result of Dr Dhingra's appointment, the board is now comprised of nine members.
Subscribe to our email newsletter
Dr Dhingra is currently heading KAPital Consulting, a company engaged in helping biotechnology, pharmaceutical and diagnostic companies realize the clinical and commercial promise of the advances in oncology.
David Hale, chairman of the board of Micromet, said: “We are honored to have Dr Dhingra join the board of directors. His significant success and proven track record in the development of oncology drugs will be a tremendous asset to Micromet as we advance our clinical stage product candidates to pivotal trials.”